

Online-only Supplement

ACTIV-6 Executive Committee..... 2

ACTIV-6 Protocol Oversight Committee 2

ACTIV-6 Clinical Trial Team..... 3

ACTIV-6 Independent Data Monitoring Committee 3

ACTIV-6 Clinical Events Classification Committee..... 4

ACTIV-6 Data Coordinating Center..... 4

ACTIV-6 Primary Site Investigators / Study Coordinators 6

COVID-19 Ordinal Outcome Scale 9

eTable 1. Baseline symptom prevalence and severity..... 10

eTable 2. Adverse events..... 12

eFigure 1. Study flow diagram..... 13

eFigure 2A. All-cause hospitalization or death for ivermectin versus placebo 14

eFigure 2B. All-cause hospitalization, urgent care, emergency room visit, or death for ivermectin versus placebo 15

ACTIV-6 Executive Committee

Adrian Hernandez, Duke Clinical Research Institute (Clinical Coordinating Center PI)
Susanna Naggie, Duke Clinical Research Institute (Clinical Coordinating Center Co-PI)
G. Michael Felker, Duke Clinical Research Institute (Medical Monitor, blinded)
Sybil Wilson, Duke Clinical Research Institute
Allison DeLong, Duke Clinical Research Institute
April Remaly, Duke Clinical Research Institute
Rhonda Wilder, Duke Clinical Research Institute
Christopher J. Lindsell, Vanderbilt University Medical Center (Data Coordinating Center PI)
Thomas G. Stewart, Vanderbilt University Medical Center
Sean Collins, Vanderbilt University Medical Center
Sarah Dunsmore, National Center for Advancing Translational Sciences
Sam Bozzette, National Center for Advancing Translational Sciences
Gene Passamani, National Center for Advancing Translational Sciences
Stacey Adam, Foundation for the National Institutes of Health
David Boulware, University of Minnesota
Elizabeth Shenkman, University of Florida
Florence Thicklin, Stakeholder Advisory Committee
Matthew William McCarthy, Weill Cornell Medicine, Stakeholder Advisory Committee
George Hanna, Biomedical Advanced Research and Development Authority

ACTIV-6 Protocol Oversight Committee

David Boulware, University of Minnesota, POC Co-Chair
Elizabeth Shenkman, University of Florida, POC Co-Chair
Adrian Hernandez, Duke Clinical Research Institute (Clinical Coordinating Center PI)
Susanna Naggie, Duke Clinical Research Institute (Clinical Coordinating Center co-PI)
G. Michael Felker, Duke Clinical Research Institute (Medical Monitor, blinded)
Sybil Wilson, Duke Clinical Research Institute
Allison DeLong, Duke Clinical Research Institute
April Remaly, Duke Clinical Research Institute
Rhonda Wilder, Duke Clinical Research Institute
Christopher J. Lindsell, Vanderbilt University Medical Center (Data Coordinating Center PI)
Thomas G. Stewart, Vanderbilt University Medical Center

Sean Collins, Vanderbilt University Medical Center
Sarah Dunsmore, National Center for Advancing Translational Sciences
Sam Bozzette, National Center for Advancing Translational Sciences
Gene Passamani, National Center for Advancing Translational Sciences
Stacey Adam, Foundation for the National Institutes of Health
Florence Thicklin, Stakeholder Advisory Committee
Matthew William McCarthy, Weill Cornell Medicine, Stakeholder Advisory Committee
George Hanna, Biomedical Advanced Research and Development Authority
Adit Ginde, University of Colorado Denver – Anschutz
Mario Castro, University of Kansas Medical Center
Dushyantha Jayaweera, University of Miami
Mark Sulkowski, John Hopkins University
Nina Gentile, Lewis Katz School of Medicine at Temple University
Kathleen McTigue, University of Pittsburgh Medical Center
Kim Marschhauser, PCORI
Julia Garcia-Diaz, Ochsner Health

ACTIV-6 Clinical Trial Team

Adrian Hernandez, Duke Clinical Research Institute (Clinical Coordinating Center PI)
Susanna Naggie, Duke Clinical Research Institute (Clinical Coordinating Center Co-PI)
G. Michael Felker, Duke Clinical Research Institute (Medical Monitor, blinded)
Sybil Wilson, Duke Clinical Research Institute
Allison DeLong, Duke Clinical Research Institute
April Remaly, Duke Clinical Research Institute
Rhonda Wilder, Duke Clinical Research Institute
Christopher J. Lindsell, Vanderbilt University Medical Center (Data Coordinating Center PI)
Thomas G. Stewart, Vanderbilt University Medical Center

ACTIV-6 Independent Data Monitoring Committee

Voting Members:

Clyde Yancy, Northwestern University Feinberg School of Medicine (Chair)
Adaora Adimora, University of North Carolina, Chapel Hill (Vice-chair)
Susan Ellenberg, University of Pennsylvania

Kaleab Abebe, University of Pittsburgh
Arthur Kim, Massachusetts General Hospital
John D. Lantos, Children's Mercy Hospital
Jennifer Silvey-Cason, Participant representative

Statistical Data Analysis Center:

Frank Rockhold, Duke Clinical Research Institute (Lead faculty statistician)
Sean O'Brien, Duke Clinical Research Institute (Faculty statistician)
Frank Harrell, Vanderbilt University Medical Center (DCC-SDAC Faculty Liaison)
Zhen Huang, Duke Clinical Research Institute (Lead statistician)

ACTIV-6 Clinical Events Classification Committee

Renato Lopes, (CEC PI)

Faculty Reviewers: W. Schuyler Jones, Antonio Gutierrez, Robert Harrison, David Kong, Robert McGarrah

Fellow Reviewers: Michelle Kelsey, Konstantin Krychtiuk, Vishal Rao

ACTIV-6 Data Coordinating Center

David Aamodt, Vanderbilt University Medical Center
JaMario Ayers, Vanderbilt University Medical Center
Jess Collins, Vanderbilt University Medical Center
John Graves, Vanderbilt University Medical Center
James Grindstaff, Vanderbilt University Medical Center
Frank Harrell, Vanderbilt University Medical Center (DCC-SDAC Faculty Liaison)
Jessica Lai, Vanderbilt University Medical Center
Christopher J. Lindsell, Vanderbilt University Medical Center (Data Coordinating Center PI)
Itzel Lopez, Vanderbilt University Medical Center
Jessica Marlin, Vanderbilt University Medical Center
Alyssa Merkel, Vanderbilt University Medical Center
Sam Nwosu, Vanderbilt University Medical Center
Savannah Obregon, Vanderbilt University Medical Center
Dirk Orozco, Vanderbilt University Medical Center
Yoli Perez-Torres, Vanderbilt University Medical Center

Nelson Prato, Vanderbilt University Medical Center
Colleen Ratcliff, Vanderbilt University Medical Center
Max Rohde, Vanderbilt University Medical Center
Russell Rothman, Vanderbilt University Medical Center
Jana Shirey-Rice, Vanderbilt University Medical Center
Krista Vermillion, Vanderbilt University Medical Center
Thomas Stewart, Vanderbilt University Medical Center (Lead statistician)
Hsi-nien Tan, Vanderbilt University Medical Center
Seibert Tregoning, Vanderbilt University Medical Center
Meghan Vance, Vanderbilt University Medical Center
Amber Vongsamphanh, Vanderbilt University Medical Center
Maria Weir, Vanderbilt University Medical Center
Nicole Zaleski, Vanderbilt University Medical Center

ACTIV-6 Primary Site Investigators / Study Coordinators

A New Start II, LLC: William (Kelly) Vincent / Raina Vincent. **Advanced Medical Care, Ltd:** Ray Bianchi / Jen Premas. **AMRON Vitality and Wellness Center, LLC:** Diana Cordero-Loperena / Evelyn Rivera. **Ananda Medical Clinic:** Madhu Gupta / Greg Karawan & Carey Ziomek. **Arena Medical Group:** Joseph Arena / Sonaly DeAlmeida. **Assuta Family Medical Group APMC:** Soroush Ramin / Jaya Nataraj. **Boston Medical Center:** Michael Paasche-Orlow / Lori Henault & Katie Waite. **Bucks County Clinical Research:** David Miller / Ginger Brounce. **Christ the King Health Care, P.C.:** Constance George-Adebayo / Adeolu Adebayo. **Clinical Trials Center of Middle Tennessee:** Alex Slandzicki / Jessica Wallan. **Comprehensive Pain Management and Endocrinology:** Claudia Vogel / Sebastian Munoz. **David Kavtaradze MD, Inc.:** David Kavtaradze / Cassandra Watson. **David Singleton MD, PA:** David Singleton / Maria Rivon & Amanda Sevier. **Del Pilar Medical and Urgent Care:** Arnold Del Pilar / Amber Spangler. **DHR Health Institute for Research:** Sohail Rao / Luis Cantu. **Diabetes and Endocrinology Assoc. of Stark County:** Arvind Krishna / Kathy Evans, Tylene Falkner & Brandi Kerr. **Doctors Medical Group of Colorado Springs, P.C.:** Robert Spees / Mailyn Marta. **Duke University:** G. Michael Felker / Amanda Harrington. **Duke University Hospital:** Rowena Dolor / Madison Frazier, Lorraine Vergara & Jessica Wilson. **Elite Family Practice:** Valencia Burruss / Terri Hurst. **Emory University:** Igbo Ofotokun / Laurel Bristow. **Essentia Health:** Rajesh Prabhu / Krystal Klicka & Amber Lightfeather. **Essential Medical Care, Inc.:** Vicki James / Marcella Rogers. **Express Family Clinic:** Pradeep Parihar / De'Ambra Torress. **Family Practice Doctors P.A.:** Chukwuemeka Oragwu / Ngozi Oguego. **First Care Medical Clinic:** Rajesh Pillai / Mustafa Juma. **Focus Clinical Research Solutions:** Ahab Gabriel / Emad Ghaly. **Franciscan Health Michigan City:** Dafer Al-Haddadin / Courtney Ramirez. **G&S Medical Associates, LLC:** Gammal Hassanien / Samah Ismail. **George Washington University Hospital:** Andrew Meltzer / Seamus Moran. **Geriatrics and Medical Associates:** Scott Brehaut / Angelina Roche. **GFC of Southeastern Michigan, PC:** Manisha Mehta / Nicole Koppinger. **Health Quality Primary Care:** Jose Baez / Ivone Pagan. **Highlands Medical Associates, P.A.:** Dallal Abdelsayed / Mina Aziz. **Hoag Memorial Hospital Presbyterian:** Philip Robinson / Julie Nguyen. **Hugo Medical Clinic:** Victoria Pardue / Llisa Hammons. **Innovation Clinical Trials Inc.:** Juan Ruiz-Unger / Susan Gonzalez & Lionel Reyes. **Jackson Memorial Hospital:** John Cienki / Gisselle Jimenez. **Jadestone Clinical Research, LLC:** Jonathan Cohen / Matthew Wong & Ying Yuan. **Jeremy W. Szeto, D.O., P.A.:** Jeremy Szeto. **Johns Hopkins Hospital:** Mark Sulkowski / Lauren Stelmash. **Lakeland Regional Medical Center:** Arch Amon / Daniel Haight. **Lamb Health, LLC:** Deryl Lamb / Amron Harper.

Lice Source Services Plantation: Nancy Pyram-Bernard / Arlen Quintero. **Lupus Foundation of Gainesville:** Eftim Adhami. **Maria Medical Center, PLLC:** Josette Maria / Diksha Paudel & Oksana Raymond. **Medical Specialists of Knoxville:** Jeffrey Summers / Tammy Turner. **Medical University of South Carolina:** Leslie Lenert / Sam Gallegos & Elizabeth Ann Szwast. **Mediversity Healthcare:** Ahsan Abdulghani / Pravin Vasoya. **Miller Family Practice, LLC:** Conrad Miller / Hawa Wiley. **North Shore University Health System/Evanston Hospital:** Nirav Shah / Tovah Klein. **Ochsner Clinic Foundation:** Julie Castex / Phillip Feliciano. **Olivo Wellness Medical Center:** Jacqueline Olivo / Marian Ghaly, Zainub Javed & Alexandra Nawrocki. **Pine Ridge Family Medicine Inc.:** Anthony Vecchiarelli / Nikki Vigil. **Premier Health:** Vijaya Cherukuri / Erica Burden. **Rapha Family Wellness:** Dawn Linn / Laura Fisher. **Raritan Bay Primary Care & Cardiology Associates:** Vijay Patel / Praksha Patel & Yuti Patel. **Romancare Health Services:** Leonard Ellison / Jeffrey Harrison. **Spinal Pain and Medical Rehab, PC:** Binod Shah / Sugata Shah. **Stanford University:** Upinder Singh / Julia Donahue & Yasmin Jazayeri. **Sunshine Walk In Clinic:** Anita Gupta / N Chandrasekar & Beth Moritz. **Tabitha B. Fortt, M.D., LLC:** Tabitha Fortt / Anisa Fortt. **Tallahassee Memorial Hospital:** Ingrid Jones-Ince / Alix McKee & Christy Schattinger. **Tampa General Hospital:** Jason Wilson / Brenda Farlow. **Temple University Hospital:** Nina Gentile / Lillian Finlaw. **Texas Health Physicians Group:** Randall Richwine & Tearani Williams / Penny Pazier & Lisa Carson. **Texas Tech University Health Sciences Center in El Paso:** Edward Michelson / Danielle Austin. **The Heart and Medical Center:** Sangeeta Khetpal / Tiffaney Cantrell, Drew Franklin & Karissa Marshall. **Trident Health Center:** Arvind Mahadevan / Madelyn Rosequist. **TriHealth, Inc:** Martin Gnoni / Crystal Daffner. **UF Health Precision Health Research:** Carla VandeWeerd / Mitchell Roberts. **University Diagnostics and Treatment Clinic:** Mark D'Andrea / Mina Aziz. **University Medical Center- New Orleans:** Stephen Lim / Wayne Swink. **University of Cincinnati:** Margaret Powers-Fletcher / Sylvere Mukunzi. **University of Florida Health:** Elizabeth Shenkman / Jamie Hensley & Brittney Manning. **University of Florida-JAX-ASCENT:** Carmen Isache / Jennifer Bowman, Angelique Callaghan-Brown & Taylor Scott. **University of Kansas – Wichita:** Tiffany Schwasinger-Schmidt / Ashlie Cornejo. **University of Miami:** Dushyantha Jayaweera / Maria Almanzar, Letty Ginsburg & Americo Hajaz. **University of Minnesota:** Carolyn Bramante. **University of Missouri – Columbia:** Matthew Robinson / Michelle Seithel. **University of Pittsburgh:** Akira Sekikawa / Emily Klawson. **University of Texas Health Science Center at Houston:** Luis Ostrosky / Virginia Umana. **University of Texas Health Science Center at San Antonio:** Thomas Patterson / Robin Tragus. **University of Virginia Health System:** Patrick Jackson / Caroline Hallowell & Heather Haughey. **Vaidya**

MD PLLC: Bhavna Vaidya-Tank / Cameron Gould. **Vanderbilt University Medical Center:** Parul Goyal / Carly Gatewood. **Wake Forest University Health Sciences:** John Williamson / Hannah Seagle. **Weill Cornell Medical College:** Matthew McCarthy / Elizabeth Salsgiver. **Well Pharma Medical Research:** Eddie Armas / Jhonsai Cheng & Priscilla Huerta.

COVID-19 Ordinal Outcome Scale

The COVID-19 outcomes for this trial are based on the World Health Organization's Ordinal Scale for Clinical Improvement and will be collected via the online system and from the medical record. The following outcomes will be assessed as part of the COVID Clinical Progression Scale:

0. No clinical or virological evidence of infection
1. No limitation of activities
2. Limitation of activities
3. Hospitalized, no oxygen therapy
4. Hospitalized, on oxygen by mask or nasal prongs
5. Hospitalized, on non-invasive ventilation or high-flow oxygen
6. Hospitalized, on intubation and mechanical ventilation
7. Hospitalized, on ventilation + additional organ support – pressors, RRT, ECMO
8. Death

eTable 1. Baseline symptom prevalence and severity

Variable	Placebo (N=774)	Active (N=817)	Overall (N=1591)
Symptom burden on study day 1, No. (%)			
None	54 (6.98)	55 (6.73)	109 (6.85)
Mild	434 (56.07)	490 (59.98)	924 (58.08)
Moderate	247 (31.91)	221 (27.05)	468 (29.42)
Severe	39 (5.04)	51 (6.24)	90 (5.66)
Symptoms on study day 1 ^a			
Fatigue, No./total (%)			
None	65/700 (9.29)	61/730 (8.36)	126/1430 (8.81)
Mild	317/700 (45.29)	365/730 (50.00)	682/1430 (47.69)
Moderate	262/700 (37.43)	238/730 (32.60)	500/1430 (34.97)
Severe	56/700 (8.00)	66/730 (9.04)	122/1430 (8.53)
Dyspnea, No./total (%)			
None	358/700 (51.14)	371/729 (50.89)	729/1429 (51.01)
Mild	255/700 (36.43)	271/729 (37.17)	526/1429 (36.81)
Moderate	82/700 (11.71)	75/729 (10.29)	157/1429 (10.99)
Severe	5/700 (0.71)	12/729 (1.65)	17/1429 (1.19)
Fever, No./total (%)			
None	519/700 (74.14)	555/729 (76.13)	1074/1429 (75.16)
Mild	140/700 (20.00)	126/729 (17.28)	266/1429 (18.61)
Moderate	36/700 (5.14)	40/729 (5.49)	76/1429 (5.32)
Severe	5/700 (0.71)	8/729 (1.10)	13/1429 (0.91)
Cough, No./total (%)			
None	85/700 (12.14)	98/729 (13.44)	183/1429 (12.81)
Mild	385/700 (55.00)	407/729 (55.83)	792/1429 (55.42)
Moderate	200/700 (28.57)	184/729 (25.24)	384/1429 (26.87)
Severe	30/700 (4.29)	40/729 (5.49)	70/1429 (4.90)
Nausea, No./total (%)			
None	504/700 (72.00)	544/729 (74.62)	1048/1429 (73.34)
Mild	143/700 (20.43)	136/729 (18.66)	279/1429 (19.52)
Moderate	38/700 (5.43)	36/729 (4.94)	74/1429 (5.18)
Severe	15/700 (2.14)	13/729 (1.78)	28/1429 (1.96)
Vomiting, No./total (%)			
None	661/700 (94.43)	690/729 (94.65)	1351/1429 (94.54)
Mild	26/700 (3.71)	29/729 (3.98)	55/1429 (3.85)
Moderate	11/700 (1.57)	8/729 (1.10)	19/1429 (1.33)
Severe	2/700 (0.29)	2/729 (0.27)	4/1429 (0.28)
Diarrhea, No./total (%)			
None	502/700 (71.71)	525/729 (72.02)	1027/1429 (71.87)
Mild	160/700 (22.86)	136/729 (18.66)	296/1429 (20.71)
Moderate	31/700 (4.43)	57/729 (7.82)	88/1429 (6.16)

Severe	7/700 (1.00)	11/729 (1.51)	18/1429 (1.26)
Body aches, No./total (%)			
None	212/700 (30.29)	234/729 (32.10)	446/1429 (31.21)
Mild	304/700 (43.43)	320/729 (43.90)	624/1429 (43.67)
Moderate	148/700 (21.14)	140/729 (19.20)	288/1429 (20.15)
Severe	36/700 (5.14)	35/729 (4.80)	71/1429 (4.97)
Sore throat, No./total (%)			
None	331/700 (47.29)	392/729 (53.77)	723/1429 (50.59)
Mild	258/700 (36.86)	247/729 (33.88)	505/1429 (35.34)
Moderate	94/700 (13.43)	64/729 (8.78)	158/1429 (11.06)
Severe	17/700 (2.43)	26/729 (3.57)	43/1429 (3.01)
Headache, No./total (%)			
None	254/700 (36.29)	285/729 (39.09)	539/1429 (37.72)
Mild	290/700 (41.43)	296/729 (40.60)	586/1429 (41.01)
Moderate	123/700 (17.57)	108/729 (14.81)	231/1429 (16.17)
Severe	33/700 (4.71)	40/729 (5.49)	73/1429 (5.11)
Chills, No./total (%)			
None	471/700 (67.29)	513/729 (70.37)	984/1429 (68.86)
Mild	165/700 (23.57)	162/729 (22.22)	327/1429 (22.88)
Moderate	55/700 (7.86)	40/729 (5.49)	95/1429 (6.65)
Severe	9/700 (1.29)	14/729 (1.92)	23/1429 (1.61)
Nasal symptoms, No./total (%)			
None	194/700 (27.71)	210/729 (28.81)	404/1429 (28.27)
Mild	356/700 (50.86)	377/729 (51.71)	733/1429 (51.29)
Moderate	128/700 (18.29)	121/729 (16.60)	249/1429 (17.42)
Severe	22/700 (3.14)	21/729 (2.88)	43/1429 (3.01)
New loss of sense of taste or smell, No./total (%)			
None	358/700 (51.14)	366/729 (50.21)	724/1429 (50.66)
Mild	158/700 (22.57)	160/729 (21.95)	318/1429 (22.25)
Moderate	81/700 (11.57)	93/729 (12.76)	174/1429 (12.18)
Severe	103/700 (14.71)	110/729 (15.09)	213/1429 (14.91)
Concomitant Medications			
Remdesivir, No. (%)	2 (0.26)	2 (0.24)	4 (0.25)
Monoclonal antibodies, No. (%)	25 (3.23)	22 (2.69)	47 (2.95)
Nirmatrelvir/ritonavir (paxlovid), No. (%)	1 (0.13)	1 (0.12)	2 (0.13)


^aNot all participants returned surveys on all days. The denominator reflects the participants who returned their survey on Day 1.

eTable 2. Adverse events


Adverse Events	Ivermectin, not taken (N=41)	Ivermectin, taken (N=776)	Placebo, not taken (N=50)	Placebo, taken (N=724)	Overall (N=1591)
Experienced any adverse event, No. (%)	1 (2.44)	24 (3.09)	0 (0.00)	27 (3.73)	52 (3.27)
Experienced a serious adverse event, No. (%)	1 (2.44)	9 (1.16)	0 (0.00)	9 (1.24)	19 (1.19)
Serious adverse events, No. (not mutually exclusive)					
COVID-19 pneumonia	0	4		4	8
Pulmonary embolism	0	1		3	4
COVID-19 pneumonia aggravated	0	1		3	4
Venous thromboembolism	0	0		2	2
Bacteremia	0	0		1	1
Diplopia	0	0		1	1
Pneumonia due to <i>Staphylococcus</i>	0	1		0	1
Pneumonia due to <i>Streptococcus</i> , group b	0	1		0	1
Acute kidney injury	1	0		0	1
Hospitalization with dyspnea	0	1		0	1
Viral bronchopneumonia	0	1		0	1
COVID-19	0	1		0	1

“Taken” refers to the participants who reported taking (or planning to take) the study drug at least once. “Not taken” refers to the participants (if any) who did not report taking the study drug.

eFigure 1. Study flow diagram




eFigure 2A. All-cause hospitalization or death for ivermectin versus placebo



Kaplan-Meier curve and 95% confidence interval (point-wise) for hospitalization or death endpoint. Hospitalization or death was a composite endpoint. Ten hospitalizations occurred with ivermectin (1.22%) as compared to nine hospitalizations with placebo (1.16%). Hospitalization was defined as source documented confirmed hospital admission exceeding 24 hours, as measured from presentation (potentially in the emergency department) to discharge. Time to hospitalization or death was defined as the number of days between receipt of study drug and hospitalization or death (whichever occurred first). The endpoint was administratively censored at 28 days.

eFigure 2B. All-cause hospitalization, urgent care, emergency room visit, or death for ivermectin versus placebo



Kaplan-Meier curve and 95% confidence interval (point-wise) for healthcare encounter or death endpoint, which was a composite endpoint. Healthcare encounter was defined as a patient-reported hospitalization, urgent care visit, or emergency department visit of any duration. Healthcare encounters occurred in 32 (3.9%) ivermectin participants and 28 (3.6%) placebo participants. Time to healthcare encounter or death was defined as the number of days between receipt of study drug and the first occurrence of the composite endpoint.